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Abstract: 
The participation of microbiota in myriads of physiological, metabolic, genetic and immunological processes shows 
that they are a fundamental part of human existence and health maintenance. The efficiency of drugs’ absorption 
depends on solubility, stability, permeability and metabolic enzymes produced by the body and gut microbiota. Two 
major types of microbiota-drug interaction have been identified; direct and indirect. The use of antibiotics is a 
direct means of targeting intestinal microbes and short-term use of antibiotic can significantly alter the microbiome 
composition. It is noteworthy that not every microbial drug metabolism is of benefit to the host as some drugs can 
shut down  microbial processes as observed in the co-administration of antiviral sorivudine with fluoropyridimide 
resulting in a toxic buildup of fluoropyridimide metabolites from blockade of host fluoropyridimide by the microbial-
sorivudine metabolite. It has been reported that many classes of drugs and xenobiotics modify the gut microbiome 
composition which may be detrimental to human health. Microbiome-drug interaction may be beneficial or 
detrimental resulting in either treatment success or failure which is largely dependent on factors such as microbial 
enzymes, chemical composition of candidate drug, host immunity and the complex relationship that exists with the 
microbiome. The effects of microbiota on pharmacology of drugs and vice versa are discussed in this review. 
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Abstrait: 
 
La participation du microbiote à des myriades de processus physiologiques, métaboliques, génétiques et 
immunologiques montre qu’ils sont un élément fondamental de l’existence et du maintien de la santé de l’être 
humain. L’efficacité de l’absorption des médicaments dépend de la solubilité, de la stabilité, de la perméabilité et 
des enzymes métaboliques produites par le corps et le microbiote intestinal. Deux types principaux d’interaction 
microbiote-médicament ont été identifiés; direct et indirect. L'utilisation d'antibiotiques est un moyen direct de 
cibler les microbes intestinaux et une utilisation à court terme d'antibiotique peut modifier de manière significative 
la composition du microbiome. Il est à noter que tous les métabolismes de médicaments microbiens ne sont pas 
bénéfiques pour l'hôte, car certains médicaments peuvent arrêter les processus microbiens observés lors de 
l'administration concomitante d'antiviral sorivudine et de fluoropyridimide, ce qui entraîne une accumulation 
toxique de métabolites de fluoropyridimide résultant du blocage du fluoropyridimide par l'hôte. métabolite 
microbien-sorivudine. Il a été rapporté que de nombreuses classes de médicaments et de xénobiotiques modifiaient 
la composition du microbiome intestinal, ce qui pourrait nuire à la santé humaine. Une interaction 
médicamenteuse-microbiome peut être bénéfique ou préjudiciable, entraînant le succès ou l'échec du traitement, 
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qui dépend en grande partie de facteurs tels que les enzymes microbiennes, la composition chimique du 
médicament candidat, l'immunité de l'hôte et la relation complexe qui existe avec le microbiome. Les effets du 
microbiote sur la pharmacologie des médicaments et inversement sont discutés dans cette revue. 
 




 The understanding of the facts that 
microbiota/microbiome play an important role 
in the lives of humans dictates how much 
microorganisms matter. Their participation in 
myriads of physiological, metabolic, genetic, 
and immunological processes shows that they 
are a fundamental part of humans’ existence 
and health maintenance. The customized 
genetic differences in the microorganisms 
exceeding the human genome also have 
significant consequences for drug reactions in 
humans. This is as a result of microbiota 
involvement in its metabolism through the 
action of enzymes and a complex host-
microbiota interaction as the host genome can 
influence the microbiome in terms of 
phenotypes and function (1,2).  
 Most drugs are designed for oral 
administration. Drugs movement through the 
gut makes them come in direct contact with 
other extra-intestinal organ such as the liver. 
Also, they encounter intestinal environmental 
conditions such as the stomach acids as well as 
coming in contact with myriads of gut 
microorganisms from small and large 
intestines. The efficiency of drugs’ absorption 
depends on solubility, stability, permeability 
and metabolic enzymes produced by the body 
and gut microbiota (3, 4). Furthermore, paren-
terally administered drugs, as well as their 
metabolites, also reach the intestines through 
biliary secretion making the gut a central 
station for drug metabolism prior to absorption 
thereby the bioavailability and distribution of 
the drug is altered (1,3). However, little is 
known about microbiome and drug interactions 
(4,5). 
 Two major types of microbiota-drug 
interaction have been identified; direct and 
indirect.Indirect interaction may involve 
competition between microbiota-derived 
metabolites and administered drugs for the 
same host metabolizing enzyme; microbiome 
reactivation of secreted inactive drug metab- 
olite; effect on the immune system and effect 
on the overall level of the metabolizing 
enzymes in the liver and intestine. Direct 
interactions include a partial or complete 
biochemical transformation of a candidate drug 
into more or less active metabolites by 
microbially-derived enzymes known as 
Microbiome-Derived Metabolism (MDM) (4). 
Although MDM has been observed about 50 
years ago it was overlooked in drug 
development. Studies that are investigating 
this process focused on specific bacterium 
against a specific drug rather than a 
systematic assessment of human gut micro- 
biome’s capability to metabolize several oral 
drugs. This problem is due to the microbiome’s 
huge complexity and the overwhelming 
technical challenge of testing several drugs 
against several isolate cultures under multiple 
conditions. More so, the unavailability of the 
global standard has hampered the reliability to 
predict undesired microbiome effect on 




 A review of microbioata as it relates to 
pharmacology of drugs was conducted. The 
materials used for the review included relevant 
published articles in journals spanning the 
period 2001 to 2019, using google and google 
scholar search engines. The keywords used for 
the search were ‘xenobiotic’, ‘microbiome’, 
‘microbiota’, ‘pharmacology’ and ‘gut micro- 
bioata’. A total of 150 articles were initially 
identified but following assessment, 53 were 
selected for the review.  
Microbiome effects on drugs  
 The use of antibiotics is a direct means 
of targeting intestinal microbes and short-term 
use of the antibiotic drug is enough to 
significantly alter the microbiome composition 
(6). A population-based study involving deep 
sequencing of gut microbiomes of 1135 
subjects showed an association between 
microbial species and 19 drug groups (7). The 
degree to which the gut microbiome is affected 
may depend on the type and number of drug 
taken either combined or singly by an 
individual. While drugs such as Non-Steroidal 
Anti-inflammatory Drugs (NSAIDs), and Proton 
Pump Inhibitors (PPIs) showed differences in 
the individual gut microbiome composition, 
drugs such as PPIs, antidepressants and 
antipsychotics showed significant association 
with single bacteria abundance (6, 8). 
Conversely, in a study, gliclazide (anti-
diabetic) pre-treated with probiotics showed 
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higher blood levels of gliclazide in treated rats 
compared with non-treated rats revealing that 
gut microbiota may mediate the degree to 
which a drug is absorbed (9). Furthermore, 
another study reported a 3-day administration 
of Lactobacillus reuteri (K8) to have reduced 
orally administered acetaminophen in mice 
while another variant of the same species (K9) 
showed no observable effect; this effect may 
be mediated by probiotic-induced-modulation 
of the gut microbial enzyme activity as 
sulfatase and arylsulfate transferase were 
increased by the probiotic and β-glucuronidase 
enzyme decreased (10). 
 
Microbiome modifications of drug 
absorption 
 The bioavailability and absorption rate 
of candidate drugs administered orally pose a 
major obstruction to drug efficiency as about 
40% of these oral drugs are no more in use as 
a result of poor bioavailability and/or pharma- 
cokinetics in the 1990s (11). The governing 
principles of absorption totally lies in the 
chemical properties of the drug and how the 
host can actively import or export the 
molecule. Early studies implied that drug 
transport may be influenced by microbiome in 
a composition-dependent manner, and multiple 
animal studies also demonstrated that the 
microbiome modulates absorption of drugs (2). 
 Among the various methods of invitro 
screening of drug absorption parameters, cell-
based drug absorption assays are one of the 
most common and readily adopted for high-
throughput screening (12). The Caco-2 cell line 
(ATCC HTB-37) is an ideal model for these 
assay types as it has the ability to differentiate 
into a monolayer homologous to the entero- 
cytes of the small intestines with characteristic 
expression of transporters which include p-
glycoprotein and OATP-A/B (2, 12). When the 
Caco-2 cells are grown on a semi-permeable 
membrane such as the Transwells, a polarized 
membrane is produced with an apical and 
basolateral chamber which is functionally 
homologous to the intestinal lumen and 
underlying circulation respectively. The apical 
to basolateral and vice versa are measured for 
a candidate drug, or suitable surrogate 
compounds such as p-glycoprotein model 
substrates digoxin, calcein-AM, or rhodamine 
123 (13, 14). Complex Caco-2 cell models such 
as the gut-on-a-chip and HuMiX models allow 
for 3D structures development including the 
villi, and divergent cell types with a relative 
enhancement of CYP3A4 activity while 
facilitating co-culture with bacterial cultures 
(2).      
 Several modes through which the 
microbiome regulatess host transport have 
been suggested, but they either include 
controlling host gene expression, llosteric 
regulators, substrate competition, or binding of 
microbial products acting as inhibitors (2). 
Through the use of quantitative reverse 
transcriptase polymerase chain reaction (qRT-
PCR) panels or RNA sequencing,  examination 
of host expression can be achieved in a 
targeted manner. Meanwhile, the examination 
of co-differentially regulated genes may give 
more insight into the pathways through which 
modulation occurs (2). For instance, p-
glycoprotein is under the control of FXR, PXR, 
AP-1 and NFκB  pathways, but the examination 
of co-regulated transcripts employing the 
pathway analysis tools may help detect the 
active specific pathway. It has been estab- 
lished that indole metabolites and other 
microbial-derived compounds function as PXR 
ligands (15, 16).    
 The intestinal lumen contains a variety 
of cell types, many of which do not have an 
absorptive function. To be able to target 
absorptive enterocytes therefore, laser capture 
microdissection or single-cell RNA sequencing 
may be employed to limit differential 
expression analyses to target cell types of 
interests. This may be essential in the case of 
genes which have functions in other cell types 
such is the case of P-glycoprotein expressed in 
phagocytes and T cells (17). 
 
Microbiome-drug metabolism  
 It is noteworthy that not every 
microbial drug metabolism is of benefit to the 
host as some drugs can shut down microbial 
processes as observed in the co-administration 
of antiviral sorivudine with fluoropyridimide 
resulting in a toxic build up of fluoropyridimide 
metabolites as a result of blockade of host 
fluoropyridimide by the microbial-sorivudine 
metabolite (2). About fifty known drugs have 
been shown to be metabolized by bacteria, 
however neither the microbial species nor the 
genetic determinants responsible for these 
drug metabolisms are known (18). Moreso, 
since there are no observable pieces of 
evidence for bacterial metabolism to have 
taken place,  the number of drugs metabolized 
by the microbiome is likely to be higher (19). 
 The discovery of high-throughput 
culturing has made screen collections and 
bacteria selection possible, representing 
extensive panels of strains for drug 
metabolism that are human-associated. It is 
possible to observe substrate loss or new 
metabolite production by the co-incubation of 
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each microbial strain or collection (synthetic 
community) with each of the desired drugs. 
While high-throughput isolate screens have the 
merit of detecting bacteria capable of drug 
metabolism with direct interpretation, high-
density plate-based culturing and robotics 
provide a superficial sampling of microbial 
genetic variation as development of analytical 
method for the drug is a primary limitation (2). 
Large chunk of the genetic variations within a 
species is achieved via horizontal gene transfer 
which is usually associated with resistance to 
antibiotics (2, 20). 
 Many phenotypes such as the ability to 
inactivate the drug digoxin, a cardiac drug, 
occurs  periodically within species (21). The 
presumptive selection of representative strains 
may likely not have the genes of interest due 
to superficial sampling at the species level; 
however, this approach has proven successful 
in the identification of multiple drug metab- 
olizing bacterial species (22). The use of ex 
vivo human stool samples incubations may be 
an alternative to culture-collection screens as 
this method has the advantage of identifying 
many of the drugs that are susceptible to 
microbial metabolism. Nonetheless, inter-strain 
antagonism may obscure metabolism when 
testing a community of microorganisms collec- 
tively and this may be true especially if these 
metabolizing microbes are impeded by anti- 
microbial products such as bacteriocins or 
organic acids of metabolically inactive strains 
(23). In addition, using media formulations, 
some microbes may be favored, conferring 
dominance on them over the entire culture. 
One method to overcome this is to perform ex 
vivo incubations through manifold media 
formulations with broad selection pressures 
ready for aerobic spore-forming Gram-positive, 
strictly anaerobic, and Gram-negative microbes 
(2). 
 Another methodology for investigating 
microbial biochemical changes from a mixed 
community is the use of faecalase preparation, 
which is a cell-free faeces extract including 
microbial enzymes (2). This method has been 
used to assess gut microbial enzyme activity 
against herbal glycosides generating genotoxic 
aglycone products (24). Also, this method has 
been used to demonstrate that lovastatin, a 
cholesterol-lowering drug can be metabolized 
by the gut bacteria (25). However, the 
presence of, or competition for, essential 
cofactors and membrane-bound coenzymes 
may lead to false-negative results in this 
methodology; these may or may not be 
present in the faecalase preparation. 
Furthermore, the secretion of cytosolic 
enzymes which may not be active in buffer 
conditions and the lack of constant generation 
of NAD(P)/FAD in the cell may inhibit metabolic 
activity and consequently, the sensitivity of 
this methodology can be problematic to define 
(21). 
 A number of approaches may be 
employed to unearth the molecular mech- 
anisms responsible for detecting metabolism. 
Since it has been established that a specific 
microbial strain is capable of metabolism, 
multi-omics can be especially informative (2). 
In the bacterial genome, genes that are 
functionally related are typically restricted and 
transcriptionally regulated as operons. After 
stimulated by a ligand, there is the induction of 
specific effector gene expression and this can 
be exploited for the identification of candidate 
effector enzymes and molecules through gene 
expression analysis such as RNA sequencing 
(RNA-seq) by differentiating expression 
between drug-exposed and vehicle controls 
(2). However, not all enzymes are subject to 
substrate-mediated transcriptional regulation 
and there is need for caution to syncronize the 
the drug-exposed cultures and growth phase of 
control prevent false-positive results stemming 
from changes in cellular physiology (19). 
 Lastly, many non-antibiotic drugs may 
have either bactericidal or bacteriostatic effects 
invitro, potentially causing serious changes in 
gene expression due to stress responses. As 
soon as specific genes are identified, their 
induction can be readily confirmed by quan- 
titative reverse transcriptase PCR (qRT-PCR) 
on independent cultures. Nonetheless, follow-
up studies are very paramount to make causal 
links between the identified genes and specific 
biochemical reactions (2). Nuclear receptors 
especially CAR, PXR, FXR and AHR regulate the 
expression levels of transporters and enzymes 
for drug-metabolizing (26,27). The CAR, PXR 
and FXR are classified members of the steroid 
receptor superfamily that regulate their 
associated genes through the formation of a 
DNA-binding heterodimer with retinoid X 
receptor (27). The CAR receptor regulates the 
following drug-metabolizing enzymes; CYP2B6 
and CYP2C9 (phase 1), UGTB1 and SULT1E1 
(phase 2) and organic anionic transport protein 
OATP1B3 (phase 3). Meanwhile PXR regulates 
CYP3A, CYP3B, CYP2B, CYP2C and GSTA1, 
UGT1A3, as well as UGT1A6 in phase 1 and 
phase 2 metabolizing enzymes respectively 
(27). Both CAR and PXR regulate overlapping 
groups of genes involved in phase 1, 2 and 3 
metabolism (27).  
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Impacts of xenobiotics and drugs on gut 
microbiome  
 It has been reported that many classes 
of drugs and xenobiotics modify the comp- 
osition of gut microbiome  which may be 
detrimental to human health. Infection by 
Clostridium difficile has been reported to be 
associated with the use of proton pump 
inhibitors by patients (28). Several drugs such 
as sulfasalazine, antibiotics, digoxin and 
phenacetin have been investigated to have the 
greatest impact on the functionality of gut 
microbiome but the degree to which antibiotic 
treatment modulates the metabolism of orally 
administered drugs is subject to further 
perusal (27). Additionally, many xenobiotics 
have been reported to modify the gut 
microbiota and most notable xenobiotic is 
arsenic which has been demonstrated in a 
mouse model to significantly decrease the 
abundance of Firmicutes which are mainly 
producers of butyrate thereby altering the 
composition of indole and glucuronide 
metabolites (27). 
 
Microbiome impacts on phytochemical 
metabolism and bioavailability 
 The most notable function of host-
microbial co-metabolism is the conversion of 
dietary plant substances into bioactive 
molecules. This role has attained accelerated 
importance with traditional medicine and 
herbal supplements now widespread (29). 
Phenolics and flavonoids are the most common 
phytochemicals most disposed in the human 
colon to microbial metabolism (27). More over, 
microbiome impact on phytochemicals includes 
metabolic changes involving esterases, de- 
methylations, glycosidases, dehydroxylations 
and decarboxylations. Curcumin is the best-
studied naturally occurring phenolics due to its 
anti-oxidant and anti-inflammatory activities. 
Its pharmacologic activity is thought to be as a 
result of tetrahydrocurcumin, a metabolite 
produced by gut microbiota. Escherichia coli 
from human faeces exhibits the highest 
curcumin metabolizing activities (27, 30). 
 
Microbiome impacts on drug/xenobiotic 
metabolism and pharmacokinetics  
 The gut microbiome uses several 
mechanisms to modify the nature, potency and 
toxicity of both drugs and xenobiotics. These 
mechanisms are achieved through; (i) express- 
ion of enzymes that either inactivate or 
activate drugs metabolically, seen in the case 
of sulfasalazine for the treatment of gut 
inflammation being converted to 5-amino 5-
salicylic acid (its active form) by microbial 
enzymes while on the other hand, digoxin is 
being inactivated by a cardiac glycoside 
produced by the bacterium Eggerthella lenta; 
(ii) the drug may be separated in order to 
store its component by binding directly to the 
bacterial organism as in the case of L-DOPA 
sequestered by Helicobacter pylori; (iii) the 
drug may be reactivated metabolically by 
expressed enzymes produced by microbes and 
an example of this mechanism is irinotecan 
(CPT-11), a drug that was previously in- 
activated in the liver via glucuronidation, being 
reactivated by bacterially expressed beta-
glucuronidase resulting in diarrhoea within the 
intestines; (iv) metabolites that function as 
intermediates may be generated by the micro- 
biota and an example is the toxicity in 
melamine as a result of the microbial formation 
of cyanuric acid (its metabolite); and (v) 
microbial p-cresol and metabolites produced by 
the host from a candidate drug acetaminophen 
may directly compete for a host enzyme 
SULT1A1 (29,31,32). Metabolic reactions of 
microbiota known to largely affect the 
bioactivity of xenobiotics and drugs comprise 
reduction, proteolysis, hydrolysis, acetylation, 
dihydroxylation, deacetylation, deconjugation 
and deglycosylation processes (27).  
 Several enzymes expressed by gut 
microbes have been identified. These include 
azoreductases which have been reported to 
metabolize the drug prontosil and neoprontosil. 
When injected intravenously, the drugs gain 
entry into the intestine  and are converted to 
sulfanilamide by gut microbiota.  Another drug, 
balsalazide is  metabolized into 5-amino- 
salicylic acid by microbially expressed enzymes 
(azoreductases). However, antibiotic treatment 
suppresses the conversion of orally admini- 
stered balsalazide into 5-aminosalicylic acid, 
prontosil and neoprontosil to sulfanilamide in 
rat respectively (3).    
 Among many studies that provide 
insight into the upcoming role of gut 
microbiome in the metabolism and pharma- 
cokinetics of drugs, bacterial nitroreduction 
reactions are of keen interest as they can 
largely affect the pharmacologic activity of 
nitroaromatic drugs such as chloramphenicol, 
2-chloro-5-nitro-N-phenoxybenzamine (GW9662), 
nitrobenzodiazepine and 5-(aziridine-1-y1)-
2,4-dinitrobenzamide (CB1954) (27). Chloram- 
phenicol, a substrate of bacterial nitroredu- 
ctase, GW9662 is an antagonist of peroxisome 
proliferator which is activated by receptor g 
and a chemo-preventive agent, while the 
principal plasma metabolite of GW996 is an 
amine metabolite. The  nitroreduction of this 
aimine metabolite by bacterial nitroreductases 
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can largely change its mutagenicity. The study 
of both nitroreduction of nitrobenzodiazepine 
(an addictive sedative in the treatment of 
anxiety and sleep disorders) resulted in further 
characterization of bacterial nitroreductases 
and its metabolism (27).  
 Nitroreductase being identified as NfsB 
is expressed by E. coli and it has been 
suggested that NfsB may be suitable for 
development of anti-addictive agents as 
nitroreduction leads to the inactivation of 
nitrobenzodiazepine. CB1954, an anticancer 
drug which is a dinitrobenzamide prodrug has 
been developed to target cancer cell through 
the delivery of NfsB transgene (33). 
Furthermore, other enzymes expressed by E. 
coli species capable of nitro and azo reductions 
under aerobic conditions comprise NfsA and 
AzoR. Other organisms capable of expressing 
nitroreductases include Bacillus spp., Myco- 
bacterium, Enterobacter and Staphylococcus 
(34). Although nitroreductases are involved in 
antibiotic resistance, their role in the meta- 
bolism of currently prescribed drugs is yet 
undetermined.  
 N-oxide reduction by bacteria lies at 
the central relationship between microbial 
enzymes and the host in the metabolism of an 
inhibitor (BILR355) of the human immuno- 
deficiency virus (HIV). BILR355 is metabolized 
by CYP3A, nonetheless, a study in which simul- 
taneous administration of BILR355 with 
ritonavir occurred, unravelled a distinct role of 
aldehyde oxidase and gut bacteria (35). The 
biotransformation of BILR355 involves a two-
step process; the first step involves the 
reduced form of N-oxide generated by the gut 
bacteria while the second step involves 
bacterially derived metabolite subject to the 
further host enzymes metabolism either by 
CYP3A or aldehyde oxidase. Nevertheless, the 
action of CYP3A is inhibited while the bacterial 
enzyme or aldehyde oxidase takes over (27, 
35).  
 The relationship between the gut 
bacterial enzymes and host cytochrome P450 
is also required in fostamatinib (tyrosine kinase 
inhibitor) metabolism. Fostamatinib is a pro- 
drug oxidatively metabolized by CYP3A4 upon 
cleavage of alkaline phosphatases. Further- 
more, a metabolite believed to have been 
formed in faeces via O-demethylation and 
dihydroxylation by gut anaerobes has been 
recognized. An invitro colon model supported 
with metabolomics has shown that cholesterol 
dissolving drug, simvastatin can be meta- 
bolized by the colon microbiota where 
anaerobes are prevalent. Simvastatin, designed 
to inhibit 3-hydroxyl-3methylglutaryl coenzy- 
me A in the liver to reduce cholesterol level is 
hydroxylated and subjected to b-oxidation, 
glutathione conjugation, and glucuronidation 
(36, 37). Other drugs metabolized by the colon 
anaerobic bacteria include ranitidine (H2 
antagonist) and prednisolone, a glucocorticoid 
agonist and anti-inflammatory agent (27). 
 Arsenic and polyaromatic hydrocarbons 
are xenobiotics that have been subjected to 
microbial metabolism in the gut (27). A study 
using a simulator of the microbiota (human 
gut) showed that colon microbiota can be 
involved in the extensive metabolism of arsenic 
(38). Sulphate reducing bacteria such as the 
Desulfovibrio desulfuricans are notable for their 
H2S production which converts monomethyl 
arsenic acid to monomethyl monothioarsenic 
which is a more noxious form of arsenic (38). 
The metabolism of polyaromatic hydrocarbons 
involves oxidation reactions by the cytochrome 
P450, followed by phase 2 conjugation with 
either glucuronic acid gluthathione or sulphate. 
Report from the simulation of human micro- 
biota shows that colonic human bacteria are 
also capable of biotransforming polyaromatic 
compounds such as naphthalene, phen- 
anthrene, pyrene, and benzo[a]pyrene. 
Micrococcus luteus has been identified to 
metabolize benzo[a]pyrene and the most likely 
enzyme involved was DszA/NtaA-like oxygen- 
nase (27, 39). 
 
Microbiome, detoxification and excretion  
 Detoxification and excretion of drugs in 
the human system are intrinsic to drug 
distribution and are basically propelled by 
hepatocytes for most medications (2). The 
proximity of the liver to the gut makes it close 
relatives linked by the biliary tract and the 
portal vein allowing for metabolite exchange 
derived by microbes and host as well as other 
compounds (2). There are evidences pointing 
to the gut-liver axis in which the microbiome 
and the liver interact through biliary excretion, 
recycling, signalling and regulation of gene 
expression (40). Furthermore, evidence also 
point to the gut-liver axis in relation to drug 
excretion. A study on differential expression of 
xenobiotic metabolism in the livers of germ-
free or conventionally raised mice suggested 
that microbial metabolites of tryptophan act as 
aryl hydrocarbon receptor (AHR) activators (2, 
41). 
 
Microbiome and drug interactions in 
anticancer therapies 
 Anticancer drugs are specially designed 
to target malignant cells but sometimes not 
without being toxic to the host cells which may 
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result in life-threatening adverse effects. 
Anticancer drugs are also faced  with challenge 
of resistance which is a major cause of 
chemotherapeutic treatment failure in human 
tumours and this failure can be partially due to 
genetic factors. However, efforts have been 
channelled into the development of more 
specific anticancer therapeutic approaches with 
lesser host cell toxicity. Immunotherapy has 
been a new paradigm in oncology where drugs 
are targeting immune cells rather than cancer 
cells, that is, the drugs are aimed at 
stimulating the host antitumor immune 
response (42).  
 The microbiome can interfere with the 
efficacy of anticancer treatment by meta- 
bolizing the drugs, inactivating or activating 
them. Also, they can modulate the immune 
system, interfere with side effects or the 
therapy modulates the microbiome (43). Both 
gut microbiota and intra-tumour bacteria can 
modulate chemotherapy and mediate its toxic 
effects. Mycoplasma infections, especially from 
Mycoplasma hominis and its presence in 
tumour tissues, have been reported in some 
types of cancers (44, 45, 46) as they are found 
to express nucleoside analogue-catabolizing 
enzymes that impairs drug efficacy (44). In a 
study involving simultaneous injection of M. 
hominis, infected colon cancer cells showed 
resistance to gemcitabine (2′,2′-difluoro- 
deoxycytidine) due to deamination to its 
inactive metabolite (2′,2′-difluorodeoxyuridine) 
in the liver (46). Other organisms, especially 
Gammaproteobacteria were reported to also 
induce gemcitabine resistance due to the 
expression of a bacterial long-form enzyme, 
cytidine deaminase. In a colon cancer mouse 
model, resistance to gemcitabine-induced by 
Gammaproteobacteria was reversed by co-
administration of ciprofloxacin, hence confir- 
ming the role of these bacteria in anticancer 
treatment failure (41,46). Invivo studies 
showed that E. coli impairs the action of 
gemcitabine as shown by  increased tumour 
volume and reduced survival. Meanwhile, 
cytotoxicity of the drug, CB1954, was 
increased by the action of nitroreductase. 
 Evidence that bacteria may influence 
the value of chemotherapy regimen, 
decreasing certain drug activities while 
enhancing the activity of others (42,45) was 
observed in microbiota response for platinum 
compounds where mice dosed with 
combination of cisplatin and Lactobacillus 
showed better treatment response. These 
perceived effects were associated with the 
modulation of VEGFA, BAX and CDKN1B genes 
expression in the tumour and to the bacterial 
enhancement of the T cell immunity (47). 
Furthermore, cyclophosphamide (CTX) treat- 
ment in tumour-bearing mice caused trans- 
location of Gram-positive bacteria such as 
Lactobacillus johnsonii, Lactobacillus plant- 
arum, Lactobacillus murinus, Barnesiella intes- 
tinihominis and Enterococcus hirae into the 
mesenteric lymph node and spleen where they 
were involved in stimulation of Th1 and Th17 
immune response. Germ-free mice treated 
with antibiotics against Gram-positive bacteria 
failed to generate this immune response and 
induced resistance to CTX in the study (43, 
48).  
 Selective Estrogen Receptor Modu- 
lators (SERMs) such as tamoxifen can 
modulate microbiome composition as they can 
be toxic for organisms such as Pseudomonas 
aeruginosa, Klebsiella pneumoniae, Acineto- 
bacter baumannii, Porphyromonas gingivalis, 
Streptococcus mutans, Enterococcus faecium 
and Bacillus stearothermophilus. No bacterial 
drug metabolism has been related to SERMs, 
but resistance to tamoxifen has been shown to 
be a reason for changes to cancer cell 
metabolism modulated by the microbiome. 
Furthermore, tranxes may be subject to 
microbial metabolism and interfere with 
bacterial LPS in activating the immune system 
(43). Poly ADP ribose polymerase (PARP) 
inhibitors are potential drugs in the future 
treatment of breast cancer as they have been 
shown to increase the diversity of gut 
microbiome. There has been no report on the 
relationship between aromatase inhibitors, 
navelbine, GnRH-analogs and the microbiome 
(43). 
 
Microbiome and anti-hypertension drugs 
 A study examined 52 common drugs of 
which 5 were anti-hypertension medications 
(β-blockers, α-blockers, ACE inhibitors, Sartan, 
and calcium channel blockers) and the 
microbiota (5). β-blockers in relation to 
Firmicutes and α-blockers in relation to 
Proteobacteria were linked to gut dysbiosis 
while no association was found between the 
microbiome and other three medications. In 
another population-based metagenomic anal- 
ysis, there was positive correlation between 
the use of ACE inhibitors/β-blockers and micro- 
biota composition. Similarly, hypertensive rats 
administered ACE inhibitors captopril showed 
reduced gut dysbiosis including decreased 
intestinal permeability, fibrosis and improved 
villi length (5). Consequently, it can be 
deduced that drugs alter the gut microbiome, 
probably removing opportunistic and adverse 
pathogenic bacterial species (5). 
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Incorporating microbiome and drug 
interaction into clinical setting  
 The influence of the microbiome on the 
effect and toxicity of drugs such as irinotecan 
(anti-cancer) and digoxin (cardiac drug) has 
been well recognized (49). In patients diag- 
nosed with metastatic colorectal cancer  
receiving irinotecan (CPT-11), the build-up of 
metabolites of CPT-11 known as SN-38 glucu- 
ronide produced from microbial β-glucu- 
ronidases caused epithelial damage resulting 
into severe diarrhoea in some patients (31). In 
the application of shotgun metagenomics and 
targeted metabolomics, there was report of a 
characterized phylogenetically diverse group of 
bacterial β-glucuronidases and transporter 
proteins associated with high production of SN-
38 glucuronide as well as possible higher risk 
of irinotecan-dependent toxicity (50). Investi- 
gating metabolomics and metagenomic basis 
of diversification in drug metabolism employing 
exvivo drug incubations with human faecal 
samples may offer putative biomarkers of drug 
effectiveness or risk of treatment failure (49). 
 Metabolic phenotyping studies of micr-
obiome-drug interaction using RNA/DNA high 
throughput sequencing with metabolomics 
have shown that the degree of complexity of 
gut microbiome related to drug metabolism 
differ between drugs (50,51,52). The main 
impediment is the comprehension of what 
microbiome features identified through pre- 
clinical studies. Using model systems or human 
faecal samples as an alternative for the gut 
microbiome will translate into accurate surro- 
gate endpoints for clinical studies. An example 
is the fact that the presence or absence of a 
candidate microbe or enzyme in a sequenced 
faecal sample may lack the ability to forecast 
drug metabolism (49). A way to overcome this 
barrier is to combine features using machine 
learning such as random forest method to 
detect the combinations of features most 
predictive of drug metabolism as this method 
can combine chemical and molecular features 
(49).     
 There are several clinical trials investi- 
gating the efficiency of probiotics to modify 
microbiome-dependent adverse drug resp- 
onses. A study of the randomized double-blind 
design set up to explore the probiotic potential 
to minimize CPT-11 induced toxicity where 
patients were randomized into probiotic and 
placebo groups respectively showed that 39% 
of participants in the probiotic group had grade 
3 to 4 diarrhoea while 61% in placebo group 
had diarrhoea (53). Another way to reduce 
CPT-11 toxicity is the targeted inhibition of 
microbial enzymes that changes the inactive 
form of the drug to its active form. β-
glucuronidase inhibitors from E. coli has been 
identified to significantly reduce CPT-11 
induced toxicity in mice but not on the 
orthologous mammalian enzyme (31). A 
clinical trial taking the safety and efficiency of 
this method into cognizance in human 
population has the possibility of producing 
useful insight into the efficiency of targeted, 
small molecule modulators of specific 




 The evident involvement of microbiome 
especially of the gut community in drug 
metabolism has been established. Also, 
microbiome-drug interaction may be beneficial 
or detrimental, resulting in either treatment 
success or failure, which is largely dependent 
on  factors such as the microbial enzymes, 
chemical composition of the candidate drug, 
host immunity and the complex relationship 
that exists with the microbiome. Despite the 
fact that several research studies have been 
conducted on this topic, there is still a large 
gap to the full understanding of the micro- 
biome involvement in drug metabolism that 
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